The last economic evaluation of pathogen reduction technology (PRT) in Canada was conducted in 2007. We reassessed the cost-effectiveness of PRT in the province of Québec (which has its own blood supplier) and included an evaluation of the potential impact of emerging pathogens on cost-effectiveness.

Study Design and Methods

Decision analytic Markov models were developed to simulate the costs and quality-adjusted life-years (QALY) associated with PRT as an addition to existing safety measures for plasma and platelet products (except for bacterial culture). Models accounted for several infectious and noninfectious transfusion reactions, recipients' productivity losses ensuing from these reactions, and the impact of PRT on platelet function. Scenario analyses were conducted to evaluate the impact of a new highly contagious human immunodeficiency virus (HIV)-like or West Nile virus (WNV)-like pathogen, assuming various epidemiological scenarios.

Results

In the base case, the incremental cost-effectiveness ratio (ICER) of PRT was estimated at $8,088,974/QALY gained. Assuming the presence of an HIV-like pathogen, the ICER was $265,209/QALY gained in the “average transmission” scenario, $1,274,445/QALY gained in the “rapid testing scenario,” and $123,063/QALY gained in the “highly contagious” scenario. Assuming the presence of a WNV-like pathogen, the ICER was $7,469,167/QALY gained in the “average transmission” scenario and $6,652,769/QALY gained in the “highly contagious” scenario.

Conclusion

The cost-effectiveness of PRT may substantially improve in the event of a new, blood-borne pathogen. Given their significant impact on cost-effectiveness, the emergence of new pathogens should be considered when deciding whether to adopt PRT.

CONFLICT OF INTEREST

The authors have disclosed no conflicts of interest.

Supporting Information

REFERENCES

1Pillonel J, Laperche S. Trends in risk of transfusion-transmitted viral infections (HIV, HCV, HBV) in France between 1992 and 2003 and impact of nucleic acid testing (NAT). Euro Surveill. 2005; 10: 5–8.
10.2807/esm.10.02.00519-en
CAS PubMed Google Scholar
2Dodd R. Managing the microbiological safety of blood for transfusion: a US perspective. Future Microbiol. 2009; 4: 807–18.
10.2217/fmb.09.63
PubMed Web of Science® Google Scholar
3Delaney KP, Hanson DL, Masciotra S, Ethridge SF, Wesolowski L, Owen SM. Time until emergence of HIV test reactivity following infection with HIV-1: implications for interpreting test results and retesting after exposure. Clin Infect Dis. 2017; 64: 53–9.
10.1093/cid/ciw666
CAS PubMed Web of Science® Google Scholar
4Moritz ED, Tonnetti L, Hewins ME, Berardi VP, Dodd RY, Stramer SL. Description of 15 DNA-positive and antibody-negative “window-period” blood donations identified during prospective screening for Babesia microti. Transfusion (Paris). 2017; 57: 1781–6.
10.1111/trf.14103
CAS PubMed Web of Science® Google Scholar
5 Center for Disease Control and Prevention. Bacterial contamination of platelets | Blood safety | CDC. Available from: https://www.cdc.gov/bloodsafety/bbp/bacterial-contamination-of-platelets.html. Accessed 05 Mar 2021.
Google Scholar
6Kundrapu S, Srivastava S, Good CE, Lazarus HM, Maitta RW, Jacobs MR. Bacterial contamination and septic transfusion reaction rates associated with platelet components before and after introduction of primary culture: experience at a US Academic Medical Center 1991 through 2017. Transfusion (Paris). 2020; 60: 974–85.
10.1111/trf.15780
CAS PubMed Web of Science® Google Scholar
7Lu W, Fung M. Platelets treated with pathogen reduction technology: current status and future direction. F1000Res. 2020; 9:F1000 Faculty Rev-40.
10.12688/f1000research.20816.1
PubMed Google Scholar
8Devine DV, Schubert P. Pathogen inactivation technologies - the advent of pathogen-reduced blood components to reduce blood safety risk. Hematol Oncol Clin North Am. 2016; 30: 609–17.
10.1016/j.hoc.2016.01.005
PubMed Web of Science® Google Scholar
9Marschner S, Goodrich R. Pathogen reduction technology treatment of platelets, plasma and whole blood using riboflavin and UV light. Transfus Med Hemother. 2011; 38: 8–18.
10.1159/000324160
PubMed Web of Science® Google Scholar
10Final report. Commission of inquiry on the blood system in Canada. Available from: https://epe.lac-bac.gc.ca/100/200/301/hcan-scan/commission_blood_final_rep-e/. Accessed 05 Apr 2021.
Google Scholar
11Custer B, Agapova M, Martinez RH. The cost-effectiveness of pathogen reduction technology as assessed using a multiple risk reduction model. Transfusion (Paris). 2010; 50: 2461–73.
10.1111/j.1537-2995.2010.02704.x
PubMed Web of Science® Google Scholar
12INTERCEPT Blood System™ for Plasma - Package Insert. Available from: https://intercept-canada.com/wp-content/uploads/sites/3/2021/02/INTERCEPT-CANADA-PACKAGE_INSERT-PLASMA_21may16.pdf. Accessed 11 Jan 2021.
Google Scholar
13Intercept® blood system for platelets - package insert – large volume (LV) processing set. Available from: https://intercept-canada.com/wp-content/uploads/sites/3/2021/07/Canada-LV_Cerus_INTERCEPT_Blood_System_for_Platelets_SPC%2,000,399-AW%20v2.0..pdf. Accessed 11 Jan 2021.
Google Scholar
14Sanders GD, Neumann PJ, Basu A, Brock DW, Feeny D, Krahn M, et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine. JAMA. 2016; 316: 1093–103.
10.1001/jama.2016.12195
PubMed Web of Science® Google Scholar
15Vamvakas E, Taswell HF. Long-term survival after blood transfusion. Transfusion (Paris). 1994; 34: 471–7.
10.1046/j.1537-2995.1994.34694295060.x
CAS PubMed Web of Science® Google Scholar
16Wallis JP, Wells AW, Matthews JN, Chapman CE. Long-term survival after blood transfusion: a population based study in the North of England. Transfusion (Paris). 2004; 44: 1025–32.
10.1111/j.1537-2995.2004.03400.x
PubMed Web of Science® Google Scholar
17Vamvakas EC. Relative safety of pooled whole blood-derived versus single-donor (apheresis) platelets in the United States: a systematic review of disparate risks. Transfusion (Paris). 2009; 49: 2743–58.
10.1111/j.1537-2995.2009.02338.x
PubMed Web of Science® Google Scholar
18Estcourt LJ, Malouf R, Hopewell S, Trivella M, Doree C, Stanworth SJ, et al. Pathogen-reduced platelets for the prevention of bleeding. Cochrane Database Syst Rev. 2017; 7:CD009072.
PubMed Web of Science® Google Scholar
19Estcourt LJ, Malouf R, Murphy MF. Pathogen-reduced platelets for the prevention of bleeding in people of any age. JAMA Oncol. 2018; 4: 571–2.
10.1001/jamaoncol.2017.5049
PubMed Web of Science® Google Scholar
20McDonald C, Allen J, Brailsford S, Roy A, Ball J, Moule R, et al. Bacterial screening of platelet components by National Health Service Blood and Transplant, an effective risk reduction measure. Transfusion (Paris). 2017; 57: 1122–31.
10.1111/trf.14085
CAS PubMed Web of Science® Google Scholar
21Hong H, Xiao W, Lazarus HM, Good CE, Maitta RW, Jacobs MR. Detection of septic transfusion reactions to platelet transfusions by active and passive surveillance. Blood. 2016; 127: 496–502.
10.1182/blood-2015-07-655944
CAS PubMed Web of Science® Google Scholar
22Benjamin RJ, Kline L, Dy BA, Kennedy J, Pisciotto P, Sapatnekar S, et al. Bacterial contamination of whole-blood-derived platelets: the introduction of sample diversion and prestorage pooling with culture testing in the American Red Cross. Transfusion (Paris). 2008; 48: 2348–55.
10.1111/j.1537-2995.2008.01853.x
PubMed Web of Science® Google Scholar
23Cohn CS, Stubbs J, Schwartz J, Francis R, Goss C, Cushing M, et al. A comparison of adverse reaction rates for PAS C versus plasma platelet units. Transfusion (Paris). 2014; 54: 1927–34.
10.1111/trf.12597
PubMed Web of Science® Google Scholar
24 Héma-Québec. Data on File.
Google Scholar
25Remis R, Palmer R, Leclerc P. Rapport sur la situation du sida et de l'infection au VIH au Québec, 1993 (1994).
Google Scholar
26Manns MP, Buti M, Gane E, Pawlotsky JM, Razavi H, Terrault N, et al. Hepatitis C virus infection. Nat Rev Dis Primer. 2017; 3:17006.
10.1038/nrdp.2017.6
PubMed Web of Science® Google Scholar
27 Institut de la statistique du Québec. Résultats de l'Enquête sur la rémunération globale au Québec - Collecte 2015. 02/22/2022.
Google Scholar
28Woolhouse M, Gaunt E. Ecological origins of novel human pathogens. Crit Rev Microbiol. 2007; 33: 231–42.
10.1080/10408410701647560
PubMed Web of Science® Google Scholar
29Marshall DA, Kleinman SH, Wong JB, AuBuchon JP, Grima DT, Kulin NA, et al. Cost-effectiveness of nucleic acid test screening of volunteer blood donations for hepatitis B, hepatitis C and human immunodeficiency virus in the United States. Vox Sang. 2004; 86: 28–40.
10.1111/j.0042-9007.2004.00379.x
CAS PubMed Web of Science® Google Scholar
30Custer B, Janssen MP, Hubben G, Vermeulen M, van Hulst M. Development of a web-based application and multicountry analysis framework for assessing interdicted infections and cost-utility of screening donated blood for HIV, HCV and HBV. Vox Sang. 2017; 112: 526–34.
10.1111/vox.12538
CAS PubMed Google Scholar
31Russell WA, Stramer SL, Busch MP, Custer B. Screening the blood supply for Zika virus in the 50 U.S. states and Puerto Rico: a cost-effectiveness analysis. Ann Intern Med. 2019; 170(3): 164–74.
10.7326/M18-2238
PubMed Web of Science® Google Scholar
32Ellingson KD, Sapiano MRP, Haass KA, Savinkina AA, Baker ML, Henry RA, et al. Cost projections for implementation of safety interventions to prevent transfusion-transmitted Zika virus infection in the United States. Transfusion (Paris). 2017; 57: 1625–33.
10.1111/trf.14164
PubMed Web of Science® Google Scholar
33 US Food and Drug Administration. FDA announces revised guidance on the testing of donated blood and blood components for Zika virus. FDA. Available from: https://www.fda.gov/news-events/fda-brief/fda-announces-revised-guidance-testing-donated-blood-and-blood-components-zika-virus. Accessed 05 Apr 2021.
Google Scholar
34Musso D, Richard V, Broult J, Cao-Lormeau V-M. Inactivation of dengue virus in plasma with amotosalen and ultraviolet A illumination. Transfusion (Paris). 2014; 54: 2924–30.
10.1111/trf.12713
CAS PubMed Web of Science® Google Scholar
35Tonnetti L, Proctor MC, Reddy HL, Goodrich RP, Leiby DA. Evaluation of the Mirasol platelet reduction technology system against Babesia microti in apheresis platelets and plasma. Transfusion (Paris). 2009; 50: 1019–27.
10.1111/j.1537-2995.2009.02538.x
Web of Science® Google Scholar
36Bouchard C, Dibernardo A, Koffi J, Wood H, Leighton PA, Lindsay LR. N Increased risk of tick-borne diseases with climate and environmental changes. Can Commun Dis Rep. 2019; 45: 83–9.
10.14745/ccdr.v45i04a02
CAS PubMed Google Scholar
37 ClinicalTrials.gov. Randomized, double-blind, controlled, parallel group study with the INTERCEPT Blood System for RBCs in regions at potential risk for Zika virus transfusion-transmitted infections and treatment use open-label extension study (2021). Available from: https://clinicaltrials.gov/ct2/show/NCT03037164. Accessed 05 Mar 2021.
Google Scholar
38 ClinicalTrials.gov. A randomized, double-blinded, controlled, parallel group, non-inferiority, phase III study to evaluate the efficacy and safety of the INTERCEPT Blood System for red blood cells in patients undergoing complex cardiac surgery procedures (2021). Available from: https://clinicaltrials.gov/ct2/show/NCT03459287. Accessed 05 Mar 2021.
Google Scholar

Citing Literature

Volume62, Issue6

June 2022

Pages 1208-1217

Cost-effectiveness of pathogen reduction technology for plasma and platelets in Québec: A focus on potential emerging pathogens

Abstract

Background

Study Design and Methods

Results

Conclusion

CONFLICT OF INTEREST

Supporting Information

REFERENCES

Citing Literature

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

Cost-effectiveness of pathogen reduction technology for plasma and platelets in Québec: A focus on potential emerging pathogens

Abstract

Background

Study Design and Methods

Results

Conclusion

CONFLICT OF INTEREST

Supporting Information

REFERENCES

Citing Literature

References

Related

Information